PerformanceMedium Risk

Myostatin Propeptide

Also known as: GDF-8 propeptide, Myostatin inhibitor propeptide

Half-life:: Unknown

Administration Routes

subcutaneous injectionintramuscular injection

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Endogenous N-terminal fragment of myostatin precursor; binds and neutralizes mature myostatin (GDF-8); naturally produced to regulate the extent of muscle inhibition

The body's own myostatin inhibitor. By supplementing the propeptide, myostatin suppression is extended, allowing greater muscle growth. More physiological alternative to Follistatin 344.

Primary Research Areas

myostatin inhibition
muscle hypertrophy
strength gain
lean mass increase

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

N-terminal propeptide of myostatin that inhibits myostatin signalling. No FDA approval, no NDA or IND. Research tool compound. Not on any FDA list. No active clinical development program.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Myostatin Propeptide

No active associated providers listed yet.